• anaplastic large ce
  • Aims -To investigate whether MUC1 mucin, a high molecular weight transmembrane glycoprotein, also known as epithelial membrane antigen (EMA), differs in its expression and degree of glycosylation between anaplastic large cell lymphoma (ALCL) and classic Hodgkin's disease (HD), and whether MUC1 immunostaining can be used to differentiate between CD30 positive large cell lymphomas. (bmj.com)
  • Systemic (nodal) anaplastic large cell lymphoma (ALCL) is a CD30 positive non-Hodgkin's lymphoma of T cell or null cell phenotype, mainly arising in lymph nodes. (bmj.com)
  • patients
  • 1 In 30-50% of cases, a chromosomal aberration such as the t(2;5)(p23;q35) translocation gives rise to expression of the anaplastic lymphoma kinase (ALK) protein, 2 identifying a subgroup of patients with systemic ALCL with excellent prognosis. (bmj.com)
  • This phase II trial studies how well alisertib works in treating patients with peripheral T-cell non-Hodgkin lymphoma that has come back after a period of improvement or has not responded to treatment. (clinicaltrials.gov)
  • cells
  • Methods/Results -Using five different monoclonal antibodies (E29/anti-EMA, DF3, 139H2, VU-4H5, and SM3) that distinguish between various MUC1 glycoforms, high MUC1 expression (50-95% of tumour cells positive) was found in 13 of 17 anaplastic lymphoma kinase (ALK) positive systemic nodal ALCLs, and in one of 20 cases of classic HD. (bmj.com)
  • 7, 10, 12, 13 Morphologically, these lymphomas may closely resemble systemic ALCL, being also characterised by CD30 positive tumour cells with abundant cytoplasm, large irregular nuclei, and a prominent single nucleolus or multiple nucleoli. (bmj.com)
  • Alisertib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. (clinicaltrials.gov)